Especially interesting, regarding HNSCC, is that Oct4 expression is universally acknowledged to be a favourable biomarker for cisplatin sensitivity in testicular cancer, but seems to predict poor cisplatin response in other cancers [36–38]. This evidence concerns the gene POU5F1 and head and neck squamous cell carcinoma.